The Goldman Sachs Group Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $16.00

UroGen Pharma (NASDAQ:URGN) had its price objective reduced by The Goldman Sachs Group from $22.00 to $16.00 in a report issued on Thursday morning,Benzinga reports. They currently have a neutral rating on the stock.

A number of other equities research analysts have also weighed in on URGN. Scotiabank assumed coverage on shares of UroGen Pharma in a report on Wednesday. They set a “sector outperform” rating and a $23.00 price objective on the stock. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price objective on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a report on Monday, March 10th. Finally, HC Wainwright reduced their price target on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $32.86.

UroGen Pharma Stock Down 6.9 %

Shares of URGN stock opened at $9.67 on Thursday. The stock’s fifty day moving average price is $10.49 and its 200 day moving average price is $11.18. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma has a 1-year low of $8.94 and a 1-year high of $20.70. The company has a market cap of $445.73 million, a price-to-earnings ratio of -3.07 and a beta of 0.80.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to analysts’ expectations of $25.25 million. On average, research analysts expect that UroGen Pharma will post -3.12 earnings per share for the current fiscal year.

Insider Activity

In other news, General Counsel Jason Drew Smith sold 7,379 shares of UroGen Pharma stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $82,202.06. Following the sale, the general counsel now owns 26,468 shares in the company, valued at $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $50,698.14. Following the transaction, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On UroGen Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the company. KLP Kapitalforvaltning AS acquired a new position in UroGen Pharma in the 4th quarter valued at $59,000. Lazard Asset Management LLC purchased a new stake in shares of UroGen Pharma during the fourth quarter worth $67,000. GAMMA Investing LLC lifted its stake in shares of UroGen Pharma by 6,908.4% in the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock worth $83,000 after buying an additional 7,392 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in UroGen Pharma during the fourth quarter worth about $101,000. Finally, BNP Paribas Financial Markets boosted its position in UroGen Pharma by 221.8% during the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock worth $109,000 after acquiring an additional 5,890 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.